| | | 20,000+ Fresh Resumes Monthly | |
|
|
| |
Click here or scroll down to respond to this candidateCandidate's Name , Ph.D.Faculty member, Kansas University Medical Center,Senior Medical Writer/Editor (part time) in Giddy, EasyEditing, Responsum HealthPHONE NUMBER AVAILABLE, EMAIL AVAILABLE; EMAIL AVAILABLEOBJECTIVE:A challenging position of Assistant Editor for Neuroscience Communications which requires qualities of a technical leader and manager with excellent customer-focused leadership. The position is based on my experience in writing news articles of various lengths for different audiences, reviewing and editing of manuscripts, abstracts and posters in neuroscience.SUMMARY OF QUALIFICATION:Expertise in multiple areas of neuroscience. Experience in reviewing and editing scientific and medical texts in Ability to clearly articulate scientific and clinical data in written and verbal communication, knowledge of AMA writing style and GPPIII andICMJE guidelines. Experience with advanced writing features in MS Word. Reliable time management skills and ability to manage expectations and time schedule associated with responding to client needs. As a researcher and editor I perform literature searches and prepare summaries of literature Knowledge of GPP3 and ICMJE as well as other best practices relative to medical writersExcellent team-working and oral and written communication skills as evidenced by:oPreparing scientific data for publication: published ~75 review and research papers.oPreparing and giving presentations in either oral or poster formats:30 oral and poster presentations at a variety of scientific meetings.Writing grant proposals for federal institutions and private foundations.Analytical skills:Analysis of complex scientific results both for laboratory experiments and published data.Ability to clearly articulate scientific and clinical data in written and verbal communication. Experience with advanced writingfeatures in MS Word and other Microsoft Office software.Editing and reviewing manuscripts for a peer-reviewed journals.Working in a goal-oriented collaborative environment.EDITOR, REVIEWER:Certificate of Outstanding reviewer in Tissue and Cell, Archives of Biochemistry and Biophysics, 2017, 2018. Certificate of Recognized reviewer in Tissue and Cell, Archives of Biochemistry and Biophysics, Experimental Eye Research, Molecular and Cellular Neuroscience, NeuroscienceLetters, FASEB, and other journals.KEY RESEARCH CONTRIBUTIONS:2001- 2016 - Research biologist and Medical writer VA Medical Center, Kansas City, MO2021 Aug 2022 Research Analyst, Hughes Hubbard &Reed LLP.Writing experience:Wrote and edited 70 manuscript for high ranking biomedical journals, all of them were published.Associate Professor - 1998 - 2001 Washington University, St. Louis, MOPerformed structure-function studies of synucleins role in health and human diseases. Studied matrix metalloproteinase 9 (MMP-9) in neurodegenerative diseases and cancer.Senior Investigator 1995-1998 University of Utah, UTIdentified a new retinal protein synoretin (g-synuclein) and investigated its role in health and diseases.Published two research papers and made 3 oral/poster presentation at ARVO meetingsAssistant Professor,1992-1995 Baylor College of Medicine, Houston, TXInvestigated genetic control of lipid metabolism and role of apolipoproteins in cardio-vascular diseasesEstablished a correlation between polymorphism in apolipoprotein III promoter region and predisposition to hyperlipoproteinemiaFound a role of apolipoprotein E (apo-E) in polymorphisms in coding region and the development of atherosclerosis and hyperlipoproteinemia.Published five articles in scientific journals.EDUCATION:Ph.D. Biochemistry and Molecular Biology, Moscow University, RussiaM.S. Biochemistry, Moscow University, RussiaB.S. Biochemistry, Moscow University, Moscow, RussiaPROFESSIONAL ACTIVITIES:Society for Neuroscience, 2010 - 2019currentAssociation for Research of Vision and Ophthalmology (ARVO) 1999 -2012Invited reviewer for peer review journals 2012- currentChief Editor Biochemistry Research International; Member of Editorial Board in Frontiers in Molecular Neuroscience, Cell Biochemistry and other 10 Scientific Journals, 2014- currentSELECTED PEER-REVIEWED PUBLICATIONS:Chapters in the books.1 A. Surguchov. Molecular and cellular biology of synucleins. International Review of Cell andMolecular Biology, 270, PHONE NUMBER AVAILABLE2 A. Surguchov. Intracellular dynamics of synucleins: Here, there and everywhere. InternationalReview of Cell and Molecular Biology, 2015, 320:103-169.3 Surguchov A. in Protein Aggregation (Editor: DA Stein). Folding and unfolding of synucleins,Nova Science Publishers, 20114 Surguchov A. Advances in Brain Research (Eds: OB. Williams, GI Wilson). Two FacedMembers of the Family: The Synucleins, 2012.5 Surguchov A. Academic Editor. Synucleins: Biochemistry and role in diseases, 2018.IntechOpen.6 Surguchov A. Reviewer of the book "Frontiers in Clinical Drug Research - Alzheimer Disorders.Bentham Science Publishers. 2018.7 Emamzadeh FN and Surguchov A. Parkinsons disease. In: Predictive imagable biomarkers forbrain disorders. June 2019, Front. Neurol. Eds: PK. Mandal, L Ersland, doi:10.3389/fneur.2019.00583.8 Surguchov A. Biomarkers in Parkinsons disease. Chapter in a book: Towards TranslatingBiomarker Research of Neurodegenerative Diseases to Clinical Practice, Neuromethods Series bySpringer Nature. Eds. P. Peplow, B. Martinez, TA Gennarelli. 2022, 173, pp. 155180.Articles in peer reviewed journalsPronin AN, Morris AJ, Surguchov A, Benovic JL. Synucleins are a novel class of substrates for Gprotein-coupled receptor kinases. J Biol Chem. 2000, 275, PHONE NUMBER AVAILABLE (>450 citations).A. Surguchov, B. McMahon, E. Masliah, I. Surgucheva. Synucleins in ocular tissues. J Neurosci Res,2001, 65, 68-77A. Surguchov, RE. Palazzo, and I. Surgucheva. Gamma synucleins: subcellular localization inneuronal cells and effect on signal transduction. Cell Motility and Cytoskeleton, 2001, 49, 218-228Surgucheva I., McMahan B, F. Ahmed, Tomarev S, Wax MB, Surguchov A. 2002. Synucleins inglaucoma. J Neurosci Res, 68: 97-106.Surgucheva I, Sivak, JM, Fini ME, Palazzo RE and Surguchov A. Effect of g-synuclein expression onmatrix metalloproteinases. Arch Biochem Biophys. 2003, 410:167-176.Maurage CA, Ruchoux MM, De Vos R, Surguchov A, Destee A. Retinal involvement in dementia withLewy bodies: A clue to hallucinations? Ann Neurol. 2003, 54 (4):542-7.Snyder HM, Mensah K, Surgucheva I, Festoff B, Surguchov A, Wolozin B. -Synuclein preventsProteasomal inhibition by -synuclein but not g-synuclein. J Biol Chem, 2005. 4; 280:7562-9.Surgucheva, B. Yue, BC Park, S Tomarev and A. Surguchov. Interaction of myocilin with g-synucleinand its role in neurodegeneration in glaucoma. Cell Mol Neurobiol, 2005, 25, 6, 1009-33Surgucheva I, Ninkina N, Buchman VL, Grasing K, A. Surguchov. Protein aggregation in retinal cellsand approaches to cell protection. Cellular Molecular Neurobiology, 2005, 25, 6, 1051-1066.Surgucheva I, McMahon B., A. Surguchov. Dynamic intracellular localization of g-synuclein: a clueto its functions. Cell Motility and Cytoskeleton, 2006, 63, 8, 447-458.Surgucheva I, Surguchov A. 2008. g-Synuclein: Cell-Type Specific Promoter Activity and Binding toTranscription Factors. J Mol Neuroscience, 2008; 35(3):267-71.A. Surguchov. Molecular and cellular biology of synucleins. International Review of Cell andMolecular Biology, 2008, 270, 225-317.I Surgucheva, A Shnyra, J Goldberg, A. Weisman and A Surguchov. g-Synuclein as a marker of theretinal ganglion cells, Molecular Vision, 2008, 14:1540-1548.I Surgucheva, V Shestopalov and A Surguchov. Effect of g-synuclein silencing on apoptoticpathways in retinal ganglion cells. J Biol Chem, 2008, 284 (52): 36377-85.A. Surguchev and A. Surguchov. Conformational Diseases: Looking into the eyes. Brain ResearchBulletin, 2010, 81, 12-24Surgucheva I, Chidambaram K, Willoughby DA, Surguchov A. MicroRNA regulates MMP-9expression. J Ocular Biology, Diseases and Bioinformatics, 2010; 3: 41-52,Surgucheva I, McMahon B, Surguchov A. Patterns of synuclein expression throughout lensdevelopment. J Biophys Chem. 2010; 1: 12-18Surgucheva I and Surguchov A. Expression of caveolins in trabecular meshwork cells and itsimplication in pathogenesis of glaucoma. Molecular Vision 2011;17: 2878-2888Surgucheva I, Sharov V; Surguchov, A. g-Synuclein: Seeding of -Synuclein Aggregation andTransmission Between Cells. Biochemistry, 2012; 51(23):4743-54Surguchov A. Synucleins: are they two-edged swords? J Neurosci Res, 2013; 91 (2):161-6.Surguchov A. Parkinsons disease: Is there a light at the end of a tunnel? (Editorial). Advances inParkinsons Disease, Nov 2013, 2, 3, 116-117.Surgucheva I, Gunewardena S, Rao HS, Surguchov A. Cell-specific post-transcriptional regulation ofg-synuclein gene by micro-RNAs. PLOS One, Sep 2013, PONE-D-13-25172Surguchov A. What do synucleins do in the nucleus? (Editorial). Journal of Genetics, Molecular andBiology, 2014, 1, 1.Surguchov A. SNCG (synuclein, gamma). Atlas Genet Cytogenet Oncol Haematol. June 2014. URL:http://AtlasGeneticsOncology.org/Genes/SNCGID42343ch10q23.htmlSurgucheva I, Newell KL, Burns J and Surguchov A. New - and g-Synuclein ImmunopathologicalLesions in Human Brain. Acta Neuropathologica Com, 2014, 2: 132.Surgucheva I, He S, Sharma R, Rich M, Ninkina NN, Stahel P, Surguchov A. Role of synucleins intraumatic brain injury. Mol Cell Neurosci. 2014, 63, 114123.Surguchev A, Surguchov A. Effect of a-synuclein on membrane permeability and synaptictransmission: a clue to neurodegeneration? J Neurochemistry, 2015; 132 (6): 619-21Surguchov A. Intracellular dynamics of synucleins: Here, there and everywhere. International Reviewof Cell Molecular Biology, 2015; 320:103-169.Surguchov A. Atlas of Genetics and Cytogenetics in Oncology and Hematology, 2015, 19, 210-217.Surguchov A. Parkinsons disease: early diagnosis and association with melanoma. Brain Sci. 2016,6(2), 17; doi: 10.3390/brainsci6020017.Surguchov A. g-Synuclein as a cancer biomarker: viewpoint and new approaches. Oncomedicine,2016, 1:1-3. doi:10.7150/oncm.16748.Surguchov A. Type-2 diabetes and Parkinsons disease: a cross-talk between main players. Journalof Diabetes Mellitus and Metabolic Syndrome, 2016, 1, 1-7.Surguchov A, Singh V, Surgucheva I, Sharma M, Singh V. New putative epigenetic mechanism ofepilepsy. Frontiers in Neurology, 2017, 8:3. doi: 10.3389/fneur.2017.00003.Surguchev AA and Surguchov A. Synucleins and gene expression: ramblers in a crowd or copsregulating traffic? Front. Mol. Neurosci. July 2017, 10, 1-7 224 doi: 10.3389/fnmol.2017.00224Surguchov A. -Synuclein Interacts with Lipoproteins in Plasma. Frontiers in MolecularNeuroscience, 2017, Nov 2, 2017. doi: 10.1007/sPHONE NUMBER AVAILABLEEmamzadeh FN and Surguchov A. Parkinsons disease: Biomarkers, Treatment, and Risk Factors .Frontiers in Neuroscience, Neurodegeneration, 12, 61230, August 2018https://doi.org/10.3389/fnins.2018.00612Surguchov A. Academic Editor of a Book: Synucleins: Biochemistry and role in diseases, 2018.IntechOpen.Surguchov A. Protein-DNA interaction: one step closer to understanding the mechanism ofneurodegeneration. October 2018, J Neurosci Res., DOI: 10.1002/jnr.24346.Surguchov A. Reviewer of the book chapter "Frontiers in Clinical Drug Research - AlzheimerDisorders. Bentham Science Publishers. 2018.Surguchev AA, Surguchov A. Integrins-A missing link in synuclein's pathogenic mechanism.J Neurosci Res. 2019 Jan 16. doi: 10.1002/jnr.24384. PMID: 30648275Surguchev AA, Emamzadeh FN, Surguchov A. Cell responses to extracellular a-synuclein.Molecules 2019, 24(2), 305; https://doi.org/10.3390/molecules24020305.Mojbafan M, Tina S, Zafarghandi Motlagh F, Surguchov A, Nilipour Y, Zeinali S. Genetic variability inIranian limb-girdle muscular dystrophy type 2B patients: An evidence of a founder effect. Mol GenetGenomic Med. 2019 Dec;7(12):e1029. doi: 10.1002/mgg3.1029Surguchov A, Emamzadeh FN, Surguchov AA. Amyloidosis and longevity: a lesson from plants.Biology, 2019, 8(2), 43; https://doi.org/10.3390/biology8020043Emamzadeh FN and Surguchov A. Parkinsons disease. In: Predictive imagable biomarkers forbrain disorders. June 2019, Front. Neurol. Eds: PK. Mandal, and L Ersland.Surguchov A. Little pigeons can carry great messages in a book: Synucleins: Biochemistry androle in diseases, IntechOpen, 2019.Surguchov A. Invertebrate Models Untangle the Mechanism of Neurodegeneration in Parkinson'sDisease. Cells. 2021 Feb 16;10(2):407. doi: 10.3390/cells10020407Surguchov A. Caveolin: a new link between diabetes and Alzheimers disease. Cell MolNeurobiology, 2020 Jan 23. doi: 10.1007/sPHONE NUMBER AVAILABLESurguchev AA, Surguchov A. A member of the ABC transporter family in healthy and ailing brain.(Editorial) Brain Sciences, February 2020, 10, 121; doi:10.3390/brainsci10020121Surguchov A. Analysis of protein conformational strains a key for new diagnostic methods.International Journal of Molecular Science, 2020, 21, 2801; doi:10.3390/ijms21082801Surguchov A. When pandemic meets epidemic: COVID-19 and neurodegenerative diseases(Editorial) Biochemistry Research International, 2020Surguchov A, Barnel L, Surguchev AA. Phytochemicals as regulators of genes involved insynucleinopathies. Biomolecules, 2021, 11 (5), 624Surguchov A Biomarkers in Parkinsons Disease. Chapter in a book Peplow PV et al., eds. NeurodegenerativeDiseases Biomarkers. 2022. Neuromethods, vol 173. pp 155-180. Humana, New York, NY.https://link.springer.com/protocol/10.1007/978-1-0716-1712-0_7Surguchov A., Surguchev AA. Synucleins: new data on misfolding, aggregation and role in diseases.Biomedicines, 2022;10 (12):3241. doi: 10.3390/biomedicines10123241.Surguchov A. alpha-Synuclein and mechanisms of epigenetic regulation. Brain Sciences, 2023, 13, 150.https://doi.org/10.3390/Surguchov A, Emamzadeh FN, Titova M, Surguchev A. Controversial properties of amyloidogenic proteins andpeptides: new data in the COVID era. Biomedicines 2023, 10, 11(4):1215. DOI: 10.3390/biomedicines11041215Scopus: https://www.scopus.com/authid/detail.uri?authorId=7003527550Website: http://genetics1972.org/Andrei/Linkedin: https://LINKEDIN LINK AVAILABLE |
